Trial Profile
Effectiveness and safety of Campath-1H [alemtuzumab] as an induction agent in combination with tacrolimus monotherapy for prevention of graft rejection compared to tacrolimus in combination with MMF [mycophenolate mofetil] and steroids [corticosteroids] in cadaveric kidney transplantation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Corticosteroids; Methylprednisolone; Mycophenolate mofetil; Prednisolone; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 18 Jun 2012 Actual patient number changed from 131 to 197 as reported by ClinicalTrials.gov.
- 09 May 2007 Status change from in progress to completed.
- 23 Nov 2005 New trial record.